AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Amneal Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$19.36+0.18 (+0.94%)

Close on Oct 19, 2026

Market cap: $6.35B
P/E (TTM): 39.5
Dividend yield: –

Amneal Pharmaceuticals, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	3,019	2,794	2,394	2,212	2,094	1,993	1,626	1,663	1,034	1,018
Cost of Revenue	1,905	1,774	1,573	1,428	1,325	1,330	1,147	939	507	421
Gross Profit	1,113	1,020	821	785	769	628	353	716	526	597
Research & Development	186	191	164	196	202	180	188	194	171	179
Selling, General & Admin	527	476	430	400	366	327	290	228	109	119
Operating Income	394	249	204	-95	153	91	-249	-20	245	285
Other Non-Operating Income	-255	-304	-245	-153	-121	-127	28	-183	-74	-70
Merger & Restructuring Charges	4.21	2.36	1.75	1.42	1.86	2.40	34	56	0	0
Asset Impairment Charges	0	0	31	13	0.71	2.68	47	39	0	0
Gain (Loss) on Sale of Assets	–	–	–	0	0	0.12	7.26	-2.96	-29	0
Legal Settlements	0.39	-97	-1.82	-270	-25	-5.86	-12	20	29	11
Pretax Income	139	-55	-40	-248	31	-36	-220	-203	171	215
Income Tax Expense	11	19	8.45	6.66	11	-104	383	-1.42	2.00	5.40
Net Income incl. Noncontrolling Interests	128	-74	-49	-255	20	69	-604	-201	169	209
Minority Interest in Earnings	56	43	35	-125	9.55	-22	-242	-33	1.68	2.05
Net Income	72	-117	-84	-271	13	68	-604	-20	0	0
Net Income to Common	72	-117	-84	-130	11	91	-362	-21	0	0
EPS (Basic)(per share)	0.23	-0.38	-0.48	-0.86	0.07	0.62	-2.74	-0.16	–	–
EPS (Diluted)(per share)	0.22	-0.38	-0.48	-0.86	0.07	0.61	-2.74	-0.16	–	–
Shares Outstanding (Basic, Weighted)(shares)	313	309	176	151	149	147	132	127	–	–
Shares Outstanding (Diluted, Weighted)(shares)	325	309	176	151	152	149	132	127	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 39.3%
Operating margin: 14.6%
Net margin: 5.0%
Return on equity, FY2025: -80.0%

Financial strength

Current ratio: 2.20
Debt to equity: 77.83
Debt to assets: 68.1%
Cash to current liabilities: 14.5%

Valuation

P/E ratio: 39.5
Price to sales: 2.04
Price to book: 192.35
Dividend yield: –